Trials / Active Not Recruiting
Active Not RecruitingNCT05739435
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
A Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Patients With Plaque Psoriasis
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 165 (actual)
- Sponsor
- Alumis Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, open-label extension (OLE) study in patients with plaque psoriasis who have completed their participation in a previous plaque psoriasis study of ESK-001.
Detailed description
This study will consist of patients who have completed their participation in a previous plaque psoriasis study of ESK-001. Each patient will be assigned to receive ESK-001 at one of two open-label dose levels. Patients have the option to remain on study until ESK-001 is commercially available.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | envudeucitinib | Oral tablet |
Timeline
- Start date
- 2023-01-17
- Primary completion
- 2026-12-01
- Completion
- 2026-12-30
- First posted
- 2023-02-22
- Last updated
- 2026-04-01
Locations
38 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05739435. Inclusion in this directory is not an endorsement.